文献速递肾癌与肾肿瘤男科与性医学

冯·希佩尔-林道病中以嗜铬细胞瘤为主亚组的特征分析

Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease.
PubMed 文献 · Urology · 2025-03-14

本研究在单中心接受肾上腺切除术且病理证实嗜铬细胞瘤的VHL患者中,预先定义「以嗜铬细胞瘤为主」表型(早发、家族史、多发嗜铬细胞瘤、副神经节瘤),并与其余队列比较基因型与表型差异。139例中110例(79%)符合最终定义;该亚组较少合并其他VHL肿瘤(包括肾细胞癌,P<.001),更易携带错义突变(P<.001)。

要点

  • 以嗜铬细胞瘤为主的VHL患者较少合并其他VHL肿瘤类型,包括肾细胞癌(P<.001)。
  • 该亚组更易携带错义突变(P<.001)。
  • 以嗜铬细胞瘤为主患者更常见0种(P<.001)或1种(P=.008)肾上腺外肿瘤类型。

核心结论

  • 以嗜铬细胞瘤为主的VHL患者表型上不同于非以嗜铬细胞瘤为主者,且显著较少合并一种以上其他VHL表现,包括肾癌。

研究设计与样本

  • 本研究中心接受肾上腺切除术且病理证实嗜铬细胞瘤的VHL患者被纳入。
  • 预先将以嗜铬细胞瘤为主VHL定义为具备以下一项或以上特征:早发(首次嗜铬细胞瘤年龄低于队列中位年龄28.2岁)、嗜铬细胞瘤家族史、多发嗜铬细胞瘤、副神经节瘤。
  • 以嗜铬细胞瘤为主患者与其余队列比较基因型和表型差异。

主要发现

  • 共检查139例VHL患者。
  • 初步分析显示早发、家族史和多发嗜铬细胞瘤三项特征相关联;副神经节瘤与其他因素不相关,故从以嗜铬细胞瘤为主定义中排除。
  • 多数患者(110/139,79%)符合最终定义。
  • 以嗜铬细胞瘤为主患者较少合并大多数其他VHL肿瘤类型,包括肾细胞癌(P<.001),而较其余队列更易携带错义突变(P<.001)。
  • 总体上,以嗜铬细胞瘤为主患者最可能具有0种(P<.001)或1种(P=.008)肾上腺外肿瘤类型,而非以嗜铬细胞瘤为主患者最可能具有4种(P=.02)或5种(P=.02)。

关键数值与推荐

  • 以嗜铬细胞瘤为主VHL最终定义:早发(首次嗜铬细胞瘤年龄低于队列中位年龄28.2岁)、嗜铬细胞瘤家族史、多发嗜铬细胞瘤(副神经节瘤因不相关被排除)。
  • 以嗜铬细胞瘤为主患者110/139(79%)符合最终定义。
  • 以嗜铬细胞瘤为主患者合并肾细胞癌较少(P<.001),携带错义突变较多(P<.001)。
  • 以嗜铬细胞瘤为主患者具有0种肾上腺外肿瘤类型(P<.001)或1种(P=.008);非以嗜铬细胞瘤为主患者具有4种(P=.02)或5种(P=.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To define a classification schema for von Hippel-Lindau (VHL) patients who have a pheochromocytoma predominant phenotyope. MATERIALS AND METHODS: VHL patients who underwent adrenalectomy with pathology-proven pheochromocytoma at our institution were included. We defined pheochromocytoma-predominant VHL a priori as patients with one or more of the following traits: early onset [age at first pheochromocytoma below the cohort's median age (28.2years)], family history of pheochromocytomas, multiple pheochromocytomas, and paraganglioma(s). Patients with pheochromocytoma-predominant disease were compared to the remaining cohort to determine differences in genotype and phenotype. RESULTS: One-hundred thirty-nine VHL patients were examined. Preliminary analysis showed that three characteristics (early onset, family history, and multiple pheochromocytomas) were associated. Having paraganglioma(s) did not correlate with the other factors, so it was excluded from the definition of pheochromocytoma-predominant disease. The majority of our patients (110/139, 79%) met the final definition. Pheochromocytoma-predominant patients were less likely to have most additional VHL tumor types, including renal cell carcinoma (P<.001) whereas they were more likely to have missense mutations (P<.001) than the remaining cohort. Overall, pheochromocytoma-predominant patients were most likely to have 0 (P<.001) or 1 (P=.008) extra-adrenal tumor types while non-pheochromocytoma-predominant patients were most likely to have 4 (P=.02) or 5 (P=.02). CONCLUSION: Pheochromocytoma-predominant VHL patients are phenotypically distinct from their non-pheochromocytoma-predominant counterparts and are significantly less likely to have more than one other VHL manifestation, including renal carcinoma.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Solomon JR, Lawson KA, Vocke CD, et al. Characterization of the Pheochromocytoma-Predominant Subgroup of von Hippel-Lindau Disease. Urology. 2025. PMID: 40090593. doi:10.1016/j.urology.2025.03.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。